LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating…
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities…
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…
Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September…
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage…
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated…
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is…
New messaging reflects TFS's commitment to patient-centered clinical research and global partnerships LUND, Sweden, Sept. 19, 2024 /PRNewswire/ -- TFS HealthScience…
New pharma agreement for Parsortix CTC analysisGUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading…
SEATTLE, WA / ACCESSWIRE / September 18, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing…